Abstract
Aims
Blood donors are of voluntary and replacement type. All donors, especially voluntary, are considered as slow risk for seropositive status for Hepatitis B and C, HIV and syphilis. The present study endeavors to screen blood donors-a slow risk group and evaluate the resultant data.
Methodology
We screened 23,068 donors serologically over 2 years for the above blood transmissible diseases. Serum alanine aminotranferase (ALT) and bilirubin were evaluated as surrogate markers in hepatitis B and C positive donors.
Results
Seroprevalence rates were found to be HIV (1.96 %), syphilis (2.15 %), hepatitis B (1.98 %) and hepatitis C (0.9 %). Majority donors were voluntary (70.37 %) and male (96.2 %). However seroprevalence rates showed no significant difference: voluntary (7.02 %), replacement (6.67 %) male (6.85 %) and female (6.95 %). HCV and HIV showed highest (29.6 %) while HBV and HCV (2.5 %) showed lowest concomitance. Serum ALT and bilirubin were not effective surrogate markers. No demographic or behavioral variable was found as a significant risk factor.
Conclusion
Thus, all donors need adequate privacy, information, counseling and motivation in order to reduce the seropositive rates in donors. Advent of sensitive tests renders surrogate markers redundant.
Keywords: Concomitance, Seroprevalence, Surrogate marker
Full Text
The Full Text of this article is available as a PDF (62.1 KB).
References
- 1.Beal R.W., Aken W.A. Gift or good? Vox Sang. 1992;63:1–5. doi: 10.1111/j.1423-0410.1992.tb01210.x. [DOI] [PubMed] [Google Scholar]
- 2.Sawanpanyalert P., Uthaivoravit W., Yanai H., et al. Donation deferral criteria for blood donors in North Thailand. Transfusion. 1996;36:242–249. doi: 10.1046/j.1537-2995.1996.36396182143.x. [DOI] [PubMed] [Google Scholar]
- 3.Nanu A., Sharma S.P., Chatterjee K., Jyoti P. Markers for transfusion transmitted infections in N. Indian donors 1989–1996. Vox Sang. 1997;73:70–73. doi: 10.1046/j.1423-0410.1997.7320070.x. [DOI] [PubMed] [Google Scholar]
- 4.Mundee Y., Kamtorn N., Chaiyaphruk S., et al. Infectious disease markers in blood donors, N. Thailand. Transfusion. 1995;35(3):264–267. doi: 10.1046/j.1537-2995.1995.35395184285.x. [DOI] [PubMed] [Google Scholar]
- 5.Alonso C., Pedroso M.L., Sanjose S., et al. Hepatitis C virus among blood donors: a followup study. Transfusion. 1994;34(6):527–530. doi: 10.1046/j.1537-2995.1994.34694295070.x. [DOI] [PubMed] [Google Scholar]
- 6.Choudhary N., Ramesh V., Sarasal S., et al. Effectiveness of mandatory transmissible disease screening in Indian blood donors. Indian J Med Res. 1995;101:229–232. [PubMed] [Google Scholar]
- 7.Jolly J.G., Sharma N.N. Screening of voluntary donors for serum hepatitis carrier state by liver function tests. Indian J Med Res. 1972;60(11):1592–1595. [PubMed] [Google Scholar]
- 8.Elavia A.J., Banker D.D. Prevalence of HBs Ag and subtypes in high risk groups and blood donors in Bombay. Indian J Med Res. 1991;93:280–285. [PubMed] [Google Scholar]
- 9.Tsai S.L., Liaw Y.F., Yeh C.T., Chu C.M., George K. Cellular Immune Response in patients with dual infection of hepatitis B and C viruses: Dominant role of hepatitis C virus. Hepatology. 1995;21(4):908–912. [PubMed] [Google Scholar]
- 10.Saha M.K., Chakrabarti S., Panda S., Naik T.N. Prevalence of HCV and HBV infection amongst HIV seropositive intravenous drug users and their noninjecting wives in Manipur, India. Indian J Med Res. 2000;111:37–39. [PubMed] [Google Scholar]
- 11.Sheen I.S., Liaw Y., Lin D., Chuc M. Role of hepatitis C and delta viruses in termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal followup study. J Infect Dis. 1994;170:358–361. doi: 10.1093/infdis/170.2.358. [DOI] [PubMed] [Google Scholar]
- 12.Hu K.Q., Yu C.H., Lee S., Villamil F., Vierling J. Simultaneous detection of both HBV DNA and HCV RNA using a combined one step polymerase chain reaction technique. Hepatology. 1995;21(4):901–907. [PubMed] [Google Scholar]
- 13.Blood safety and Irational use of blood Chapter 17. NACO and MDACS-Training manual for doctors; 2000:174–180
- 14.Reesink H.W., Nydegga U.E. Editorial.Vox Sang. 1992;63:59–69. doi: 10.1111/j.1423-0410.1992.tb01221.x. [DOI] [PubMed] [Google Scholar]
- 15.Shimoyama R., Kato T., Ikeda H., Sekiguchi S. Followup of HBV and HCV carriers in blood center, Japan. Vox Sang. 1998;75:257–258. doi: 10.1046/j.1423-0410.1998.75302572.x. [DOI] [PubMed] [Google Scholar]
- 16.Prayura K. Thailand: More than 600,000 HIV infections. AIDS-Asia. 1994;3:12. [Google Scholar]
- 17.Arankalle V.A., Chadha M.S., Jha J., Amrapurkar D.N., Banerjee K. Prevalence of anti HCV antibodies in West India. Indian J Med Res. 1995;101:91–93. [PubMed] [Google Scholar]
- 18.Deloris K., Paul M., Olland V., et al. Antibody to hepatitis B core antigen as a paradoxical marker for Non A, Non B hepatitis agents in donated blood. Ann Int Med April. 1986;104(4):488–495. doi: 10.7326/0003-4819-104-4-488. [DOI] [PubMed] [Google Scholar]
- 19.Paul J.R., Michael B., Girish V. Analysis of HCV RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors. Hepatology. 1993;17(2):188–195. doi: 10.1002/hep.1840170205. [DOI] [PubMed] [Google Scholar]